

Curriculum Vitae for: Bruna Pellini Ferreira, MD
April, 2025

Current Position: Assistant Member
Department of Thoracic Oncology
Moffitt Cancer Center
12902 Magnolia Drive
Tampa, FL 33612
Phone: (813) 745-8666
Fax: (813)745-3027
Email: Bruna.Pellini@Moffitt.org

Education:
2007 - 2012 MD, Universidade Federal do Rio Grande do Sul (UFRGS),
Faculdade de Medicina, Porto Alegre, Brazil

Postgraduate Training and Fellowship Appointments

2017 – 2020 Medical Oncology Fellowship, Washington University
School of Medicine, St. Louis, MO

2014 – 2017 Internal Medicine Internship and Residency, University of Central
Florida, Orlando, FL

Academic Appointments and Employment:

2020 – Present Assistant Professor, Department of Oncologic
Sciences Morsani College of Medicine, University of
South Florida

2020 – Present Assistant Member, Department of Thoracic Oncology
Moffitt Cancer Center

2013 – 2014 Primary Care Physician, Multiclinica Serviços de Saúde,
São Leopoldo, Brazil

Licenses:

2020 – Present Licensed Physician, State of Florida -Active

Board Certifications:

2019 – Present American Board of Internal Medicine-Medical Oncology
Certification

2017 – 2024 American Board of Internal Medicine-Internal Medicine
Certification

2013 – Present Educational Commission for Foreign Medical Graduates
(ECFMG)

Languages Spoken: English- Advanced
Spanish - Intermediate
Portuguese – Native

Teaching Experience

1. University Courses:

2010 **Teaching Assistant:** Health and Society, Family Medicine Department, Universidade Federal do Rio Grande do Sul (UFRGS), Faculdade de Medicina, Porto Alegre, Brazil

2008-2009 **Teaching Assistant:** Medical Immunology, Department of Microbiology, Universidade Federal do Rio Grande do Sul (UFRGS), Faculdade de Medicina, Porto Alegre, Brazil

2. Teaching and Training Experience:

2015-2017 **Resident Instructor:** Internal Medicine Residency Program, University of Central Florida College of Medicine

Undergraduate Students:

2021-2022 **Ishika Patel**, Bachelor of Science, Health Sciences, University of South Florida. Mentoring in two research projects that led to two published manuscripts listed below.

Medical Students mentoring:

2023-present **Madeline Baker**, MD Candidate Class of 2027, University of South Florida Morsani School of Medicine. Mentoring in a case report and a clinical trial manuscript writing.

2022-present **Keishla Arce**, MD Candidate Class of 2025, Ponce Health Science University. General career development advice, clinic shadowing in the summer of 2022, and collaboration on a project titled “ Minority patient-centered education initiative to increase knowledge about clinical trials in thoracic oncology”. She was awarded a medical student scholarship by Fundacion Intellectus under my mentorship (\$5,000), was selected for the Cancer Care Delivery and Outcomes Research Fellowship at the Dana Farber Cancer Institute, has published two peer-reviewed manuscripts, and has presented two posters.

2022-present **Tadana Vazquez**, MD Candidate Class of 2025, Ponce Health Science University. General career development advice, clinic shadowing in the summer of 2022, and collaboration on a project titled “ Minority patient-centered education initiative to increase knowledge about clinical trials in thoracic oncology”. She was awarded a medical student scholarship by Fundacion Intellectus under my mentorship (\$2,490) and has published one peer-reviewed manuscript.

- 2019-2020 **Vishwanath Ganesan, MD.** Mentoring and collaborating on a project titled “Clinical characteristics and outcomes in patients with *KRAS* G12C-mutant non-small cell lung cancer”, which was presented as poster at the IASLC WCLC 2020. He was a MS4 at University of Missouri-Kansas City School of Medicine. He is now an Internal Medicine Resident at Cleveland Clinic, OH.
- 2019-2020 **Noah Earland B.S.** MD/PhD Candidate Class of 2026, Washington University School Medicine. Mentoring and collaborating on a project assessing ctDNA MRD in patients with locally advanced esophageal cancer, and on a project titled “Chemoradiation with cisplatin-etoposide versus carboplatin- etoposide in limited stage small cell lung cancer”. The latter has been presented as a poster at IASLC WCLC 2020

Resident Mentoring/Advising:

- 2020 **Giordano F. Cittolin Santos, M.D.** Mentorship for hematology/oncology fellowship application. Dr. Citolin has completed his residency in 2020 and was a hematology/oncology fellow at Washington University in St. Louis.
- 2020 **Adriana Matutino Kahn, M.D.** Mentorship for hematology/oncology fellowship application. Dr. Kahn has completed her residency in 2020 and is was a Breast Medical Oncologist at Yale University.
- 2014-2017 **Nway Ko Ko, M.D.** General mentorship for residency application and during residency at University of Central Florida College of Medicine. Dr. Ko Ko has completed her residency in 2018 and is currently a cardiology fellow at Mayo Clinic in Arizona.

Fellow Mentoring:

- 2021-2022 **Misty Shields, M.D., Ph.D.,** Medical Oncology/Hematology Fellow, Moffitt Cancer Center. General career development advice and research mentorship including joint publication in several manuscripts listed below. She is currently a physician-scientist at Indiana University.
- 2021-2022 **Brian Schlick, M.D.,** Medical Oncology/Hematology Fellow, Moffitt Cancer Center. Mentoring in several research projects including one published manuscript listed below.
- 2021-2022 **Julian Marin-Acevedo M.D.** Medical Oncology/Hematology Fellow, Moffitt Cancer Center. General career development advice and research mentorship including joint publication in two manuscripts listed below. He is currently a clinical investigator at Indiana University.
- 2020 **Felipe Batalini, M.D.** General career development mentorship. He is currently a clinical investigator at Mayo Clinic, Arizona.

Research Scholar:

2019-2020 **Sorrapong Manyanont, M.D.**, Department of Medicine, Division of Oncology, Washington University School of Medicine. Mentoring and collaborating on a project titled “Clinical characteristics and outcomes in patients with *KRAS* G12C mutated non-small cell lung cancer”, which was presented as a poster at IASLC WCLC 2020.

Hospitalist:

2020 **Syed Hasan, M.D.**, Department of Medicine, Washington University School of Medicine. I mentored Dr. Hasan in a projected titled “Chemoradiation with cisplatin-etoposide versus carboplatin-etoposide in limited stage small cell lung cancer” presented as a poster at IASLC WCLC 2020.

Undergraduate Lectures:

2023 USF ENCOURAGE-Diversity Program. Networking Teas. University of South Florida/Moffitt Cancer Center, Tampa, FL. July 12, 2023.

Residency Lectures:

2023 USF Radiation Oncology Residents Didactics. Neoadjuvant and Adjuvant Treatment Strategies in NSCLC. Moffitt Cancer Center, Tampa, FL. September 15, 2023.

2020-2023 Noon Conference to USF Internal Medicine Interns and Residents. Approach to the patient with a lung mass. Moffitt Cancer Center, Tampa, FL. (7 lectures)

Fellow Lectures:

2024 Hematology/Medical Oncology Teaching Conference: Metastatic NSCLC. Moffitt Cancer Center, Tampa, FL. September 16, 2024.

2023 Hematology/Medical Oncology Teaching Conference: Metastatic NSCLC (negative driver mutations). Moffitt Cancer Center, Tampa, FL. September 18, 2023.

2022 Hematology/Medical Oncology Teaching Conference: Metastatic NSCLC. Moffitt Cancer Center, Tampa, FL. September 19, 2022.

2020 Hematology/Medical Oncology Teaching Conference: Oligometastatic NSCLC and Immunotherapy for metastatic NSCLC. Moffitt Cancer Center, Tampa, FL. October 18, 2020.

2020 Hematology/Medical Oncology Teaching Conference: Updates on the Management of Extensive-Stage Small-Cell Lung Cancer. Moffitt Cancer Center, Tampa, FL. October 18, 2020.

Post-Doctoral Lectures:

2021 Molecular Epidemiology of Cancer Lecture Series: Individualized Drug Therapy: Genetics and Expression Analysis. Moffitt Cancer Center, Tampa, FL. March 11, 2021

Honors and Awards

1. 2024 Junior Faculty Research Award for Clinical Science, Moffitt Cancer Center, February 25, 2025
2. 2023 George Edgecomb Society Pilot Research Award. Awarded by the George Edgecomb Society at Moffitt Cancer Center. July 2023-present.
3. 2023 ARTES Leadership Course for Early Career Investigators. Awarded by North America Star Consortium (NASC). July 2023-present.
4. 2023 Travel Award, Summit on Thoracic Malignancies. Awarded by Dava Oncology. April, 2023.
5. Robert A. Winn Diversity in Clinical Trials Career Development Award (Winn CDA). Awarded by the Bristol Myers Squibb Foundation. November 2022-present.
6. Research Reimbursement Award. NIH grant number 3P30CA076292-23S2 (John Cleveland, PI). Awarded by GMaP Region 2/ H.Lee Moffitt Cancer Center. August, 2022.
7. Research Reimbursement Award. NIH grant number 3P30CA076292-23S2 (John Cleveland, PI). Awarded by GMaP Region 2/ H.Lee Moffitt Cancer Center. June, 2022.
8. Footsteps to Funding Grant Writing Workshop, NIH GMaP grant number 3P30CA076292-23S2 (John Cleveland, PI). Awarded by GMaP Region 2/ H.Lee Moffitt Cancer Center. March, 2022.
9. Cancer Genomics Research STRENGTH Scholarship, NIH grant number R25CA190190. Awarded by Washington University, 2018-2020.
10. FDA/ASCO Fellows Day Workshop, Silver Spring, MD. Awarded by FDA/ASCO 2019.
11. Alpha Omega Alpha Honor Medical Society, Zeta Chapter, FL. Awarded by Alpha Omega Alpha Honor Medical Society, 2016.
12. Best Poster Award, Annual Quality and Safety Forum, Orlando VA Medical Center, Orlando, FL Awarded by Orlando VA Medical Center, 2016.
13. Clinical Skills Award, University of Central Florida College of Medicine, Internal Medicine Residency Program Awarded by University of Central Florida College of Medicine 2015.
14. Junior Researcher Grant Awarded by CNPq Brazil (National Council for Scientific and Technological Development) 2010-2012
15. Junior Researcher Grant Awarded by FAPERGS (Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul) 2009-2010.

Research Support

External Grants

Account #: TBD
Name of PI: Heather Jim, PhD
Role: Co-Investigator
Dates of Project: 04/01/2025-03/31/2025
Funding Source: The Florida Department of Health

Award: Florida Cancer Innovation Fund
Title: **Patient-Reported Outcomes as Novel Biomarkers for Monitoring Cancer Progression and Response to Treatment: A Validation Study**
Effort: 5%
Total Award: \$1,561,399

Account #: 84-22885-01-01
Name of PI: Bruna Pellini, MD
Dates of Project: 10/01/2024-09/31/2026
Funding Source: Merck
Title: **Pilot Study of Circulating Tumor DNA (ctDNA) in a Prospective Cohort of Patients with Limited-stage Small Cell Lung Cancer (LS-SCLC)**
Effort: 8%
Total Award: \$192,187

Account #: 10-22605-99-01
Name of PI: Egan, K.
Role: Co-Investigator
Dates of Project: 07/15/2024 - 06/30/2026
Funding Source: NIH/NCI
Award # 1R21 CA293440-01
Title: **Epidemiologic Study of Microplastic Pollution in Bronchoalveolar Lavage Fluid and Its Association with Lung Cancer**
Effort: 0.24 CM (2%)
Total Award: \$425,772

Account #: 21-20660-05-01
Name of PI: Jeffrey Lancet, MD
Role: Co-Investigator
Dates of Project: 03/01/2020-02/28/2025
Funding Source: NIH/NCI; PTE: University Health Network – Canada
Award #: 4UM1-CA186644-07 (PTE #: 410013075)
Title: **North American Star Consortium**
Effort: 5%
Total Award: \$936,805 (Subaward total)

Internal Grants

Account #: 09-33451-23-04
Protocol #: MCC 22561
Name of PI: Bruna Pellini, MD
Dates of Project: 07/01/2023-06/30/2025
Funding Source: Moffitt Cancer Center
Award: 2023 George Edgecomb Society Pilot Research Award
Title: **Minority patient-centered education initiative to increase knowledge about clinical trials in thoracic oncology**
Effort: 5% (until 06/30/2024)
Total Award: \$75,000

Completed

External Grants

Account #: 69-22202-01-01
Name of PI: Brunna Pellini, MD
Dates of Project: 11/01/2022-10/31/2024
Funding Source: Bristol Myers Squibb Foundation
Award: Robert A. Winn Diversity in Clinical Trials Career Development Award (Winn CDA)
Title: **Culturally tailored educational videos to increase clinical trial knowledge for minority patients with lung cancer**
Effort: 40%
Total Award: \$239,874

Account #: 10-22747.01.15
Name of PI: Wright, KL/Monteiro, A (MPIs)
Role: Co-Investigator
Dates of Project: 05/15/2024-08/31/2024
Funding Source: NIH/NCI
Award: U54 CA163068
Title: **2/2 Ponce Health Sciences University-Moffitt Cancer Center Partnership**
Effort: 18%
Total Award: \$24,986 (Subaward total)

Account #: 10-20083-99-01
Name of PI: Doug Cress, PhD
Role: Co-Investigator
Dates of Project: 01/01/2022-08/01/2024
Funding Source: NIH/NCI
Award #:1R21CA259215-01A1
Title: **Molecular Drivers of Lung Cancer in Hispanics**
Effort: 2.0%
Total Award: \$236,321

Account #: 84-18843-01-02
Name of PI: Dr. Theresa A. Boyle
Role: Co-Investigator (since 09/01/2020)
Dates of Project: 12/23/2019 – 11/30/2022
Funding Source: Bristol Myers Squibb (BMS)
Title: **Use of Tumor Samples from Rapid Tissue Donation to Explore Inflammation, Mechanisms of I-O Resistance, and Tumor Neoantigen Landscape.**
Effort: 5.0%
Total Award: \$1,641,564

Account #: HRPO 201903142 (NCT04354064)
Name of PI: Aadel Chaudhuri, MD, PhD
Role in the Study: Co-Investigator
Dates of Project: May 2019-July 2020
Funding Source: Washington University School of Medicine, St. Louis, MO
Project Title: **Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment**

of Solid Tumors

The goal of this project is to investigate ctDNA as a biomarker to identify molecular residual disease (MRD) and predict disease recurrence.

Selected Clinical Trials:

Active

Account #: MCC 23090

Name of Institutional PI: Dr. Bruna Pellini

Dates of Project: September 2024– Present

Funding Source: Revolution Medicines

Project Title: **Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors**

Account #: MCC 21074

Name of Institutional PI: Dr. Bruna Pellini

Dates of Project: July 2022– Present

Funding Source: Memorial Sloan Kettering Cancer Center

Project Title: **“A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant ctDNA in Plasma After Initiation of Osimertinib”**

Account #: MCC 20373

Name of Institutional PI: Dr. Bruna Pellini, **COOPERATIVE GROUP TRIALS**

Dates of Project: September 2020 – Present

Funding Source: NCCN

Project Title: **Carboplatin+ Pemetrexed+ Bevacizumab w/w/o Atezolizumab for Stage IV NSCLC EGFR Mutation/Non-Smokers**

Account #: MCC 21184

Name of PIs: Dr. Jhanelle Gray and Dr. Bruna Pellini, **Investigator Initiated Trial**

Dates of Project: September 2021 – Present

Funding Source: Moffitt Cancer Center

Project Title: **Thoracic Program Trial Selection Protocol**

Completed

Account #: MCC 23071

Name of Institutional PI: Dr. Bruna Pellini

Dates of the project: August 2024- October 2024

Funding Source: Revolution Medicines

Project Title: **A Phase 1, Open-label Study of Oral BDTX-4933 in Patients with KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms**

Account #: MCC 21850

Name of Institutional PI: Dr. Bruna Pellini

Dates of the project: March 2023- September 2024

Funding Source: Revolution Medicines

Project Title: **Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion**

Study of RMC-6291 Monotherapy in Subjects with Relapsed/Refractory KRASG12C Mutant Solid Tumors

Account #: MCC 22068

Name of Institutional PI: Dr. Bruna Pellini

Dates of Project: February 2023- March 2024

Funding Source: Navirre

Project Title: A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation Protocol Status

Account #: MCC 20409

Name of Institutional PI: Dr. Bruna Pellini

Dates of Project: April 2022-November 2023

Funding Source: Dizal (Jiangsu) Pharmaceutical Co., Ltd

Project Title: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation

Selected Clinical Trials Pending Activation:

Account #: MCC 23183

Name of Institutional PI: Dr. Bruna Pellini

Dates of Project: Pending

Funding Source: Revolution Medicines

Project Title: A Platform Study of RAS (ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

Account #: 23419

Name of PI: Dr. Bruna Pellini- Investigator Initiated Trial

Dates of Project: Pending

Funding Source: NCI/CTEP

Project Title: 10660-A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation

Account #: 23683

Name of PI: Dr. Bruna Pellini- COOPERATIVE GROUP TRIALS

Dates of Project: Pending

Funding Source: NCI

Project Title: A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)

Biomarker/Tissue Studies

Account #: 09-33450-19-02
Project #: TCW 00343
Name of PI: Bruna Pellini, MD— **Investigator Initiated Study**
Dates of Project: 11/15/2022-present
Funding Source: MCC
Investigator Initiated Trial (IIT)
Title: **Longitudinal plasma genotyping for the detection of mechanisms of resistance to RAS inhibitors**

Account #: 02-25999-21-57/10.19249.05.15
Name of PI: Bruna Pellini, MD— **Investigator Initiated Study**
Project #: TCW 00335
Dates of Project: 06/2022-present
Funding Source: MCC/ U54
Title: **Circulating Tumor DNA (ctDNA) Dynamics after Concurrent Chemoradiation in Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC)**
Total Award (U54): \$20,000.00

Account #: MCC 17820
Name of PI: Dr. Theresa Boyle
Role: Co-PI— **Investigator Initiated Study**
Dates of Project: March 2017-Present
Funding Source: Bristol Myers Squibb (BMS/ LCCOE)
Project Title: **“Establishing and Maintaining a Rapid Tissue Donation Program”**

Account #: MCC 20768 (#02-25999-21-72)
Name of PIs: Dr. Liang Wang and Dr. Erin Siegel
Role: Co-Investigator— **Investigator Initiated Study**
Dates of Project: October 2020-Present
Funding Source: Moffitt Cancer Center
Project Title: **“Effect of sample preparation methods on cancer biomarker detection of extracellular vesicles and other plasma components”**

Service

Moffitt Cancer Center

2024 – Present	Member , Scientific Review Committee, meets monthly 3 hr.
2021 – 2024	Member , THRIVE Committee, meets monthly 1 hr.
2020 – Present	Member , Lung Cancer Center of Excellence (LCCOE) Committee, meets monthly 1.5 hrs.
2020 – 2023	Member , Lung and Thoracic Tumor Education (LATTE) Committee, meets monthly 1 hr.
2020 – Present	Member , Thoracic Tumor Board, meets weekly 2 hrs.
2020 – Present	Member , Thoracic Faculty Research Committee, meets monthly 1 hr.
2020 – 2024	Member , Thoracic Minority Accrual Task Force, meets monthly 1 hr.
2020 – 2022	Member , Lung Cancer Screening Committee, meets monthly 1h.
2020 – 2022	Physician Leader , Thoracic Honors Inclusion, Diversity & Equity

Committee, meets monthly 1hr.

Community Outreach

- 2025 U54 Outreach Core-Latinos y El Cáncer. Speaker. The Importance of Hispanic/Latino participation in Clinical Trials & Lung Cancer Treatment. March 1, 2024. Tampa, FL
- 2024 KRAS Kickers at Moffitt. Chair & Speaker. Kicking KRAS-mutant Lung Cancer. November 6, 2024. Tampa, FL
- 2023 Kick KRAS Expert Series: On the Road at Moffitt. Chair & Speaker. Overcoming treatment resistance in KRASG12C-mutant NSCLC. February 3, 2023. Tampa, FL.
- 2022 Pasco County Health Fair. Increasing Lung Cancer Survival Through Prevention, Early Detection, and Clinical Research. May 14, 2022. Wesley Chapel, FL.

Invited Lectures for patients:

- 2023 Moffitt's Thoracic Oncology Program Webinar. Speaker. Liquid Biopsies in Thoracic Oncology. November 23, 2023. Tampa, FL
- 2021 Virtual Thoracic Oncology Webinar. Liquid Biopsies: impact on treatments and plans for the future. April 29, 2021 (virtual).

USF Service

- 2024 Grant Writing Academy for Hem/Onc Fellows. Speaker. Personal Statement/NIH Biosketch. University of South Florida. June 24, 2024. Tampa, FL
- 2024 Grant Writing Academy for Hem/Onc Fellows. Speaker. Introduction to Clinical Grant Writing. University of South Florida April 1, 2024. Tampa, FL.
- 2021– Present DCE Preceptor Program, Morsani College of Medicine, University of South Florida.
- 2020 Interviewer, Moffitt/USF Hematology/Oncology Fellowship Program Selection.

National Committee/Service

- 2023 – Present **Member**, Lung Translational Medicine Subcommittee, Southwest Oncology Group (SWOG)
- 2022 – Present **Co-Chair**, Liquid Biopsy Scientific Interest Group, National Institute of Health (NIH)

International Committees

- 2024 – Present **Member**, ASCO Annual Meeting Scientific Program Committee, Lung

2024 – Present Cancer-Metastatic Non-Small Cell Lung Cancer Track
Member, ASCO Stage IV Non-Small Cell Lung Cancer Living Guideline Panel

2024 – Present **Member**, Membership Committee, International Society for Liquid Biopsy

2024 – Present **Member**, Education Committee, International Society for Liquid Biopsy

2023 **Member**, Program Committee, Translational Science, IASLC 2023 North America Conference on Lung Cancer (NACLC 2023)

Journal Editor

2024 – Present **Editorial Board Member**, *JCO Oncology Advances*.

2023 – Present **Editorial Board Member**, *The Journal of Liquid Biopsy*.

2022-2023 **Guest Editor**, Liquid Biopsies joint virtual special issue: *Cancer Treatment and Research & Communications & Translational Oncology*.

Journal Reviewer

2022-present Ad Hoc Reviewer, *Cancers*

2021-present Review Editor, Thoracic Oncology, *Frontiers in Oncology*

2021-present Ad Hoc Reviewer, *Journal of Oncology Precision Oncology*

2021-present Ad Hoc Reviewer, *BMC Cancer*

2021 Ad Hoc Reviewer, *Cancer*

2021 Ad Hoc Reviewer, *Journal of Thoracic Disease*

2019 Ad Hoc Reviewer, *Gut*

2018 Ad Hoc Reviewer, *Rare Tumors*

2017 Ad Hoc Reviewer, *Cureus*

Grant Reviewer

2024 American Lung Association (ALA), Lung Cancer Discovery Award

2020 Cancer Research UK

Invited Speaker

2025 Northside Hospital Cancer Institute 2025 Symposium. Clinical Applications of ctDNA: Current and Future Perspective. Speaker. March 29, 2025. Atlanta, GA

2025 IASLC 2025 Targeted Therapy of Lung Cancer Meeting. Women in Thoracic Oncology. Speaker. February 21, 2025. Huntington Beach, CA

2025 Winter Lung Cancer Conference. Recent Updates in the Management of Small Cell Lung Cancer (SCLC). Speaker. February 1, 2025. Hollywood, FL

2025 Winter Lung Cancer Conference. BRAF Combinations & MET. Speaker. February 1, 2025. Hollywood, FL

2025 Winter Lung Cancer Conference. Symposium: Cases and Conversations™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive

- NSCLC. Speaker. January 31, 2025. Hollywood, FL
- 2025 Early Lung Cancer Summit. Speaker. The Importance to Use ctDNA to Detect Minimal Residual Disease (MRD). January 24, 2025. Hollywood, FL
- 2024 Moffitt/AJMC Institute for Value-Based Medicine. Speaker. ctDNA Monitoring in Metastatic NSCLC. December 12, 2024. Tampa, FL
- 2024 Updates in Cancer Therapies-A Review of the 2024 ASCO & ESMO Meetings. Speaker. Targeted Therapy in NSCLC. December 6, 2024. Miami, FL
- 2024 Lung Lives LATAM. Speaker. Emerging Biomarkers in Lung Cancer & Advancements in Therapeutic Targets for NSCLC. November 22, 2024. Rio de Janeiro, Brazil (Virtual).
- 2024 IASLC 2024 Latin America Conference on Lung Cancer (LALCA). Speaker. Moving Liquid Biopsies to the Front-Line in Lung Cancer Diagnosis & Bispecifics and CAR T-Cell Therapy. November 14-16, 2024. Bogota, Colombia.
- 2024 Master DOT Rounds. Speaker. How to obtain the best outcomes for patients with resectable NSCLC harboring EGFR or ALK genomic alterations? October 10-11, 2024. Sao Paulo, Brazil
- 2024 World Conference on Lung Cancer (WCLC) 2024. Speaker. Addition of Cytotoxic Chemotherapy to Targeted Therapy: Friends or Foes? September 10, 2024. San Diego, CA
- 2024 AstraClass Brazil. Speaker. Molecular Testing in Thoracic Oncology. July 25, 2024. Sao Paulo, Brazil (Virtual)
- 2024 MD Anderson General Medical Oncology Grand Rounds. Speaker. ctDNA for Treatment Response Monitoring and MRD Assessment in NSCLC. July 17, 2024. Houston, TX (Virtual)
- 2024 Best of ASCO Miami. Speaker. Clinical Utility of Liquid Biopsies in Solid Tumors from Diagnosis to Tumor Tracking and Resistance. July 12, 2024. Miami, FL
- 2024 AZpire Oncology Summit. Speaker. The use of ctDNA and future perspectives. June 14, 2024. Sao Paulo, Brazil (Virtual)
- 2024 Brompton Grand Rounds in Thoracic Surgery. Speaker. Management of positive ctDNA after complete resection. June 14, 2024. London, United Kingdom (Virtual).
- 2024 MSD Colombia Multidisciplinary-Context of Neoadjuvant in Lung Cancer. Speaker. Neoadjuvant & adjuvant therapy for NSCLC. May 17, 2024. Bogota, Colombia

- 2024 New Frontiers in Liquid Biopsy: Data, Technology and Translational Potential. Speaker. Foundations in ctDNA testing after curative-intent treatment in NSCLC. May 13-14, 2024. Bethesda, MD
- 2024 Sylvester Cancer Center/University of Miami Conference Series. Speaker. Improving Survival in 1st-line mNSCLC with Dual Checkpoint Blockade. March 15, 2024. Miami, FL.
- 2024 2023 in Review- Lung Cancer. Panelist. Block 4: Treatment of metastatic NSCLC with a driver mutation. March 2, 2024, Sao Paulo, Brazil. (virtual)
- 2024 Ponce Health Sciences University Cancer Seminar Series. Speaker. Minority patient-centered education initiative to increase knowledge about clinical trials in thoracic oncology. March 2, 2024. Ponce, Puerto Rico.
- 2024 13th Annual Winter Cancer Symposium. Speaker. Liquid Biopsies to Guide Targeted Therapy. March 1-3, 2024. Rio Grande, Puerto Rico.
- 2024 IASLC 2024 Targeted Therapies of Lung Cancer Meeting. Speaker. ES05.03: Novel Biomarkers: ctDNA for molecular response and MRD detection. February 21-24, 2024. Santa Monica, California.
- 2024 21st Annual Winter Lung Cancer Conference. Speaker. Is there a Role for ctDNA to Tailor Therapy in Early-Stage Lung Cancer Patients? February 2-4, 2024. Hollywood, FL.
- 2024 Moffitt State of Science Symposium. Speaker. Liquid biopsies and the platforms. January 24, 2024. Tampa, FL.
- 2024 20th Annual MCM Tampa Edition. Speaker. Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue. January 19-21, 2024. Tampa, FL.
- 2023 2023 North America Conference on Lung Cancer. Speaker. Inequities in Biomarker Testing: current state and future goals. December 1-3, 2023. Chicago, IL.
- 2023 18th Annual New York Lung Cancer Symposium. Speaker. MRD Assessment in Lung Cancer. November 11, 2023. New York City, NY.
- 2023 2023 Symposium of The Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center- CTIC. Speaker. Neoadjuvant immunotherapy in lung cancer. October 27-28, 2023. Bogota, Colombia.
- 2023 FLASCO Fall Session. Speaker. Liquid Biopsy Update- Lung Cancer Update. October 20-21, 2023. Orlando, FL.
- 2023 AZPIRE Precision Oncology. Speaker. ctDNA in Medical Oncology: Clinical and Research applications. September 22, 2023. Sao Paulo, Brazil

- (virtual).
- 2023 Rocky Mountain Oncology Society Annual Conference. Speaker. ctDNA in Medical Oncology: Clinical and Research applications. September 6, 2023. Denver, Colorado.
- 2023 18th Annual New Orleans Summer Cancer Meeting. Speaker. ctDNA in Lung Cancer? Current State and Future Perspectives. July 14-16, 2023. New Orleans, LA.
- 2023 Making the Right Call: Biomarker Testing and Targeting in NSCLC: Treating Acquired Resistance and Evaluating Next-generation Therapies. Speaker. July 10, 2023. Miami, FL.
- 2023 ASCO Direct Highlights Miami Symposium. Speaker. Liquid Biopsies and Cancer: The Role of NGS, CTCs, Exosomes, cfDNA and cfRNA. July 7-8, Miami, FL.
- 2023 2nd Annual Hawaii Global Summit on Lung Cancer. Speaker. Circulating tumor DNA monitoring informs maintenance outcomes in patients with advanced NSCLC treated with induction atezolizumab + carboplatin + nab-paclitaxel. Kona, Hawaii. June 27- July 1, 2023.
- 2023 1st Annual Moffitt Solid Tumor Symposium. Speaker. Role of Biomarkers in NSCLC & Immunotherapy Updates in Non-Small Cell Lung Cancer. April 29, 2023. Tampa, FL.
- 2023 MSD Global Biomarker Webcast Summit 3. Speaker & Panelist. Current state of ctDNA testing in precision oncology. Presented on March 1, 2023 (Virtual).
- 2022 GBOT 2022 (Brazilian Thoracic Oncology Group National Symposium). Keynote Speaker: Liquid biopsies in lung cancer- Concepts and Applicability. Presented on November 19, 2022. Sao Paulo, Brazil (Virtual). *Lecture presented in Portuguese.
- 2022 XI Educational Symposium of the Spanish Lung Cancer Group. Speaker. Monitoring minimal residual disease (MRD) could arrive to clinical practice? Presented on November 17, 2022. Barcelona, Spain (Virtual). *Lecture presented in Spanish.
- 2022 International Society for Liquid Biopsy (ISLB) 4th Annual Congress Liquid Biopsy – Discussant, Preferred Abstracts. Presented on October 21, 2022. Miami, FL.
- 2022 2022 Current Trends in Immuno-oncology (CTIO) Latin America- Speaker. Overview of ctDNA biology and ctDNA testing & current state of ctDNA in precision medicine. September 20, 2022 (Virtual).
- 2022 Grupo Pardini (Brazil) & AstraZeneca Liquid Biopsy Seminar-Speaker. Liquid Biopsy in the precision medicine era. September 25, 2022. Brazil.

(Virtual) *Lecture presented in Portuguese.

- 2022 ASCO Update 2022. ASCO Direct Switzerland-Speaker. The Advent of ctDNA in Oncology. June 18, 2022. Switzerland. (Virtual).
- 2022 ASCO Annual Meeting. Clinical Science Symposium. ctDNA: Dawn of a New Era. The Advent of ctDNA in Oncology. Presented on June 4, 2022. Chicago, IL.
- 2022 10th International Lung Cancer Symposium. Liquid Biopsies: current and future applications. Presented on March 11, 2022. Sao Paulo, Brazil (Virtual). *Lecture presented in Portuguese.
- 2022 The 19th Annual Winter Lung Cancer Conference. *KRAS* (G12C vs. non-G12C). Speaker. Presented on February 6, 2022. Miami, FL.
- 2021 IASLC 2021 World Conference on Lung Cancer. Discussant. OA20.03: Exploring Treatment Modalities and Tools in Locally Advanced NSCLC. Presented on September 13, 2021 (Virtual).
- 2021 ASCO Education Expert Answers Series: Implications for Molecular Testing in Advanced Lung Cancer. Discussant. Presented on October 1, 2021 (Virtual).
- 2021 ASCO Annual Meeting. Education Session. Immune Checkpoint Inhibitors: Extending the Benefit. CPI with Chemo, Friends or Foes? Presented on June 4, 2021 (Virtual).
- 2021 OncLive Institutional Perspectives in Cancer: Lung. Updates on the Management of Extensive-Stage Small Cell Lung Cancer. April 14, 2021 (Virtual)
- 2021 American Lung Cancer Screening Initiative Webinar. Understanding Lung Cancer Screening and Treatment Options. Virtual Webinar held on March 9, 2021
- 2020 2nd Annual Leadership, Empowerment, and Development (LEAD) meeting. Precision Medicine: From Histology to Molecular Subsets. Presented on October 2, 2020 (Virtual).

Invited Speaker (Non-CME)

- 2023 VuMedi Educational Platform. Updated biomarker prevalence and testing guidelines: newly actionable biomarker *KRAS*^{G12C}, *EGFR* exon 20, and *HER2*. February 13, 2023. Virtual
- 2021 VuMedi Educational Platform. Maintenance Therapy in Patients With Extensive-Stage SCLC: Phase III IMpower 133 Trial data presented At WCLC 2020. Virtual educational session recorded on May 13, 2021.

2021 Moffitt Cancer Center Molecular Medicine Monthly Program meeting. Liquid biopsies for ctDNA MRD detection in solid tumors. Virtually held on March 26, 2021.

Invited Chair/Panelist

2025 2025 Oklahoma Thoracic Oncology. Session 5 - Current Standards and Emerging Therapies. Session Chair. March 21, 2025. Oklahoma City, OK

2024 6th Annual Congress Liquid Biopsy. Panelist. PCC Consortium- Expanding access and adoption of Liquid Biopsy in routine clinical care: Expert Insights, Practical Solutions, and Your Chance to Join the Conversation. November 23- November 25, 2024. Denver, CO.

2024 2024 ASCO Annual Meeting. Chair. Clinical Science Symposium. Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community. June 1, 2024. Chicago, IL.

2024 New Frontiers in Liquid Biopsy: Data, Technology and Translational Potential. Panelist. Career Development and Scientific Collaborations Session. May 13-14, 2024. Bethesda, MD

2024 2023 in Review- Lung Cancer. Panelist. Block 4: Treatment of metastatic NSCLC with a driver mutation. March 2, 2024, Sao Paulo, Brazil. (virtual)

2023 2023 North America Conference on Lung Cancer. Chair. ES05: Advances in Diagnostic Techniques from Blood to Bronch. December 1-3, 2023. Chicago, IL.

2020 2nd Annual Leadership, Empowerment, and Development (LEAD) Meeting. Panelist. Solid Tumor Clinical Panel Discussion. Virtually held on October 2, 2020.

2015 47th Annual Scientific Meeting of the ACP Florida Chapter. Panelist. Interviewing for Residency Fellowship & Beyond. September 12, 2015. Tampa, FL.

Professional Association Memberships

2022 – Present **Member**, International Society of Liquid Biopsies (ISLB)

2020 – Present **Member**, International Association for the Study of Lung Cancer (IASLC)

2019 – Present **Member**, American Association for Cancer Research (AACR)

2016 – Present **Member**, Alpha Omega Alpha Honor Medical Society (AOA)

2015 – Present **Member**, American Society of Clinical Oncology (ASCO)

Peer-Reviewed Publications

1. Leighl NB, Ismaila N, Durm G, Florez N, Freeman-Daily J, **Pellini B**, Mishra DR, Schenk EL, Sequist L, Singh N, Bazhenova L. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3. *J Clin Oncol*. 2025 Feb 27;JCO2402786. doi: 10.1200/JCO-24-02786. Epub ahead of print. PMID: 40014838.
2. Le X, Patel JD, Shum E, Baik, C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall, R, Elamin, YY, Tu, J, Blumenschein G, Zhang J, Gibbons, D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, **Pellini B**, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve *EGFR*-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). *J Clin Oncol*. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8. PMID: 39378386
3. Vince M, Naqvi SMH, **Pellini B**, Verbosky M, Melzer D. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer. *Lung Cancer*. 2024 doi.org/10.1016/j.lungcan.2024.107999
4. Baker MC, Rose TA, **Pellini B**. Discrepancy Between Liquid Biopsy and Tumor Next-Generation Sequencing Due to Low Tumor Fraction in a Patient With Lung Adenocarcinoma. *Cureus*. 2024. doi.org/10.7759/cureus.70119
5. Ozakinci H, Song X, Nazario GS, Lila T, Chen B, Simpson T, Nguyen JV, Moran Segura CM, Thompson ZJ, Thapa R, Rose TA, Haura EB, **Pellini B**, Yu X, Ruffell BH, Chen DT, Boyle TA, Beg AA. Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung Adenocarcinoma. *J Immunol*. 2024 Oct 1;213(7):1033-1041. doi: 10.4049/jimmunol.2400234.
6. Walls GM, **Pellini B**, Chaudhuri AA. Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer. *The Journal of Liquid Biopsy*. 2024. doi.org/10.1016/j.jlb.2024.100160. PMID: 38587480
7. **Pellini B**, Chaudhuri AA. Racial Disparities in Early-Stage NSCLC Treatment: A Call for Action. *Cancer Epidemiol Biomarkers Prev*.2024. doi.org/10.1158/1055-9965.EPI-24-0339. PMID: 38587480
8. Desai A, Vázquez TA, Arce KM, Marcelo Corassa M, Philip C. Mack PC, Jhanelle E Gray JE*, **Pellini B***. ctDNA for the Evaluation and Management of *EGFR*-mutant Non-Small Cell Lung Cancer. *Cancers*. 2024. doi.org/10.3390/cancers16050940. PMID: 38473302
9. Gilardone S, Thapa R, Laborde J, Shafique MS, Saltos A, Creelan B, Tanvetyanon T, Chiappori A, Simon G, Haura E, Gray J, Chen DT, Melzer D*, **Pellini B***. Osimertinib versus Afatinib as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer with an *EGFR* Exon 19 Deletion or Exon 21 L858R Mutation. *J Thorac Dis*. 2023. doi.org/10.21037/jtd-23-686. PMID: 38090314
10. Semenkovich NP, Samson PP, Stowe HB, Badiyan SN, Vlacich GR, Wang YE, Star R, Devarakonda S, Govindan R, Waqar S, Robinson CG, **Pellini B**, Chaudhuri AA. Pre-

radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer. *npj Precision Oncology*. 2023. doi.org/10.1038/s41698-023-00440-6. PMID: 37783809

11. **Pellini B***, Madison RW*, Childress M, Miller ST, Cheng J, Huang RSP, Krainock M, Gupta P, Zou W, Shames DS, Moshkevich S, Ballinger M, Liu MC, Young A, Srivastava MK, Oxnard GR, Socinski MA. Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2023. doi.org/10.1158/1078-0432.CCR-23-1578. PMID: 37702716
12. Imbody D, Arce K, Solanko HS, Haura EB, **Pellini B**. Targeting SHP2 Signaling in Lung Cancer. *J Thorac Oncol*. 2023;S1556-0864(23)00729-3. doi:10.1016/j.jtho.2023.08.009. PMID: 37574134
13. Semenkovich NP, Badiyan SN, Samson PP, Stowe HB, Wang YE, Star R, Devarakonda S, Govindan R, Waqar SN, Robinson CG, Vlacich G, **Pellini B***, Chaudhuri AA. Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer. *NPJ Preci Oncol*. 2023 Oct 2;7(1):100. doi: 10.1038/s41698-023-00440-6.
14. Bodor JN, Patel JD, Wakelee HA, Levy BP, Borghaei H, **Pellini B**, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab with and without Atezolizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. *Clinical Lung Cancer*. 2023; ISSN 1525-7304 <https://doi.org/10.1016/j.clcc.2023.05.003>.
15. Garcia D, Marin-Acevedo J, **Pellini B**. Subcutaneous immune checkpoint inhibitors: friends or foes? *ASCO Daily News*. May 18, 2023.
16. **Pellini B**, Chaudhuri AA. ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?. *Clin Cancer Res*.2023. <https://doi.org/10.1158/1078-0432.CCR-23-0420>
17. Marin-Acevedo J*, **Pellini B***, Kimbrough EMO, Hicks JK, Chiappori A. Treatment Strategies for Non-Small Cell Lung Cancer with *EGFR* mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. *Cancers*. 2023; 15(3):629. <https://doi.org/10.3390/cancers15030629>.
18. Soupir AC, Tian Y, Stewart P, Nunez Lopez Y, Manley BJ, **Pellini B**, Zhang J, Mo Q, Marchion DC, Liu M, Koomen J, Siegel EM, Wang L. Detectable lipidomes and metabolomes by different plasma exosome isolation methods in cancer patients and healthy controls. *Int J Mol Sci*. 2023. 24(3):1830. <https://doi.org/10.3390/ijms24031830>.

19. Shields MD, Chen K, Dutcher G, Patel I, **Pellini B**. Making the rounds: Exploring the role of circulating tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. *Int J Mol Sci*. 2022 Aug 12;23(16):9006 <https://doi.org/10.3390/ijms23169006>. PMID: 36012272
20. Schlick B, Shields MD, Marin-Acevedo J, Patel I, **Pellini B**. Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer. *Curr Treat Options Oncol*. 2022 Aug;23(8):1104-1120. <https://doi.org/10.1007/s11864-022-00989-7>. Epub 2022 Jun 18. PMID: 35716328
21. Luo J, Ostrem J, **Pellini B**, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC. Overcoming *KRAS*-Mutant Lung Cancer. *Am Soc Clin Oncol Educ Book*. 2022. Apr;42:1-11. PMID: 35412860.
22. **Pellini B**, Chaudhuri AA. ctDNA MRD Detection of Non-Small Cell Lung Cancer Treated with Curative-Intent. *J Clin Oncol*. 2022 Jan 5;JCO2101929. PMID: 34985936
23. Huang J, Soupir AC, Schlick BD, Teng M, Sahin IH, Permeth JB, Siegel E, Manley BJ, **Pellini B***, Liang Wang*. Cancer detection and classification using CpG island hypermethylation signatures in plasma cell-free DNA. *Cancers* 2021;Nov 9; 13(22):5611. PMID: 34830765
24. Chen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, Reimers MA, Zevallos JP, Davis AA*, **Pellini B***, Chaudhuri AA*. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. *Mol Diagn Ther*. 2021 Nov;25(6):757-774. PMID: 34725800
25. Devarakonda S*, **Pellini B***, Verghese L, Park H, Morgensztern D, Govindan R, Suresh R, Oppelt P, Baggstrom M, Wu N, Waqar S. A phase II study of everolimus in patients with advanced solid malignancies with *TSC1*, *TSC2*, *NF1*, *NF2* or *STK11* mutations. *J Thorac Dis* 2021 Jul; 13(7):4054-4062. doi: 10.21037/jtd-21-195. PMID: 34422335.
26. **Pellini B**, Johnson T, Gray JE. Disparities in cancer research: Understanding the Present with a Historical Context. *ASCO Daily News*. April 7, 2021.
27. Shields MD, Marin-Acevedo JA, **Pellini B**. Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. *Am Soc Clin Oncol Educ Book*. 2021 Mar;41:1-23. PMID: 33979196.
28. **Pellini B***, Pejovic N*, Feng W*, Earland N, Harris PK, Usmani A, Szymanski JJ, Qaium F, Mudd J, Petty M, Maher CA, Henke LE, Park H, Ciorba MC, Kim H, Mutch MG, Pedersen KS, Tan BR, Hawkins WG, Fields RC, Chaudhuri AA. ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine. *JCO Precis Oncol*. 2021 Feb 12;5:PO.20.00276. doi: 10.1200/PO.20.00276. PMID: 34250420.
29. Chaudhuri AA*, **Pellini B***, Pejovic N, Chauhan PS, Harris PK, Szymanski JJ, Smith ZL, Arora VK. Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. *JCO Precis Oncol*. 2020 Jul 15;4:PO.20.00060. doi:10.1200/PO.20.00060. PMID: 32923907.

30. **Pellini B**, Szymanski JJ, Chin RI, Jones PA, Chaudhuri AA. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. *Thorac Surg Clin*. 2020;30(2):165-177. PMID: 32327175
31. Jacobs MT, Olson M, **Ferreira BP**, Jin R, Hachem R, Byers D, Witt C, Ghobadi A, DiPersio JF, Pusic I. The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. *Am J Transplant*. 2020;20(2):589-592. PMID 31446673
32. Cadore E, Graudenz M, **Pellini Ferreira B**, Schulz R, Borba C, Uchoa D, Wagner M. Claudins 1,3,4,7, and 10-year survival in triple-negative breast tumors. *Mastology*. 2019;29(2):71-78.
33. **Pellini Ferreira B**, Vasquez J, Carilli A. Metastatic hepatoid carcinoma of the pancreas: first description of treatment with capecitabine and temozolomide. *Am J Med Sci*. 2017;353(6):610-612. PMID: 28641727
34. **Pellini Ferreira B**, et al. Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. *Laryngoscope*. 2017;127(7):1583-1588. PMID: 27905113
35. Uchôa Dde M, Graudenz MS, Callegari-Jacques SM, Hartmann CR, **Ferreira BP**, Fitarelli-Kiehl M, Edelweiss MI. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas – a study of series of triple-negative tumors. *Pathol Res Pract*. 2014;210(7):432-439. PMID 2472626
36. Schneider L, Oliveira DS, Strapasson ACP, **Ferreira BP**, Molina CG, Stopiglia CDO, Fischer G, Scroferneker ML. White blood cell game: a teaching method. *International Journal of Health Promotion and Education*. 2012 Nov; 50(6): 311-317.
37. **Ferreira BP**, Rodler ET, Loggers ET, Pollack SM, Jones RL. Systemic therapy in primary angiosarcoma of the spleen. *Rare Tumors*. 2012;4(4):e55. PMID 23372919

*Indicated co-authorship, co-senior authorship, or corresponding authorship

Book Chapters

1. **Pellini Ferreira B**, Morgensztern D. (2019). Cell-Free DNA in Cancer Diagnosis and Follow-up. In: Ramaswamy Govindan, Siddhartha Devarakonda, editors. *Cancer Genomics for the Clinician*. New York: Springer Publishing Company; p.117-128. ISBN 9780826168672
2. **Ferreira B.P.**, Gullet A., Pollack S.M., Jones R.L. (2014). Targeting Oncogenic Pathways in Dermatofibrosarcoma Protuberans and Inflammatory Myofibroblastic Tumor. In: Linda M. McManus, Richard N. Mitchell, editors. *Pathobiology of Human Disease*. San Diego: Elsevier; p. 1995-2002.

Scientific Abstracts/Oral Presentations/ Poster Presentations

Scientific Abstracts

1. **Pellini B**, Li J, Schell M, Tanvetyanon T, Creelan B, Chiappori A, Saltos A, Antonia S, Haura E, Shafique M, Rose T, Khalil F, Vafadar S, Smikker S, Melendez M, Aminpour A, Sansil A, Wermuth J, Sanchez AA, Ugrenovic M, Monteiro A, Rix U, Gray JE. A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer (SqCLC). *JCO* 42, 8545-8545 (2024). doi:10.1200/JCO.2024.42.16_suppl.8545
2. Yang JCH, Doucet L, Wang M, Fan Y, Sun M, Greillier L, Planchard D, Mazieres J, Felipe E, **Pellini B**, Bosch-Barrera J, Cobo M, Bearz A, Paz-Arez LG, Bazhenova L, Shum E, Tiseo M, Soto Parra H, Zheng L, Janne PA. A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study. *JCO* 42, 8513-8513 (2024). doi:10.1200/JCO.2024.42.16_suppl.8513
3. Ozakinci H, Nazario G, Stern YE, Solanki HS, Chen D-T, Rose T, Schabath MB, Stewart P, Teer J, Beg A, Boyle TA, Haura EB, **Pellini B**. Rapid autopsy provides unique research opportunity to evaluate KRAS^{G12C} inhibitor resistance mechanisms in non-small cell lung cancer. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA. October 11-15, 2023. Philadelphia (PA): AACR; *Mol Cancer Ther* 2023;22(12 Suppl):Abstract nr C046.
4. Janne PA, Bigot F, Papadopoulos K, Eberst L, Sommerhalder D, Lebellec L, Voon PJ, **Pellini B**, Kalinka E, Arbour K, Herzberg B, Boni V, Bodernave S, Lee HW, Ou SI, Riess JW, Beck JT, Ponz-Sarvise M, Ascierto PA, Choi YJ, Tan D, Yang M, Bao L, Raman R, Yang L, Mu Y, Wong S, Dua R, Johnson M. Preliminary Safety and Anti-Tumor Activity of RMC-6291, a First-in-Class, Tri-Complex KRASG12C(ON) Inhibitor in Patients With or Without Prior KRASG12C(OFF) Inhibitor Treatment. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA. October 11-15, 2023. Philadelphia (PA): AACR; *Mol Cancer Ther* 2023;22(12 Suppl):Abstract nr PR014.
5. Semenkovich N, Samson P, Badiyan S, Vlacich G, Stowe H, **Pellini B**, Robinson C, Chaudhuri AA. Abstract #54319. Circulating tumor DNA for early risk stratification of oligometastatic lung cancer. ASTRO's 65th Annual Meeting, Oct 1-4, 2023. San Diego, CA.
6. Stewart P, Solanki H, Welsh E, Stern Y, Imbody D, Zhang Y, **Pellini B**, Fang B, Yoder S, Eschrich S, Teer J, Koomen J, Haura EB. Proteogenomic landscape of KRAS^{G12C} lung adenocarcinomas reveals new subtypes and potential combination therapies. *Mol Cancer Res* 1 May 2023; 21 (5_Supplement): A007. doi.org/10.1158/1557-3125.RAS23-A007
7. Ozakinci H, Nazario G, Colossi Furlan K, Chen D-T, Rose T, Schabath MB, Haura EB, **Pellini B**, Beg A, Boyle TA. Rapid tissue donation identifies LAG3 as a potential therapeutic target for ALK fusion positive lung cancer. *Cancer Res* 1 April 2023; 83 (7_Supplement): 6642. doi.org/10.1158/1538-7445.AM2023-6642

8. Saeed L, Ozakinci H, Majumder A, Nazario G, Macaulay R, Bossler A, **Pellini B**, Beg A, Haura E, Boyle T. Post-Therapy Samples Collected Through Rapid Tissue Donation Confirms the Necessity of Tissue-Based Next Generation Sequencing in Identifying Driver Mutations. Abstract #G033. AMP 2022 Annual Meeting Nov 1-5 2022 Phoenix AZ Abstract #1301928.
9. Soupir AC, Stewart P, Manley BJ, **Pellini B**, Zhang J, Mo Q, Marchion DC, Koomen J, Siegel E, Wang L. Abstract 3417: Effects of plasma exosome isolation methods on detectable multiomic profiles in cancer patients and healthy controls. *Cancer Res* 15 June 2022; 82 (12_Supplement): 3417. doi.org/10.1158/1538-7445.AM2022-3417
10. **Pellini B**, Pejovic N, Feng W, Earland N, Harris PK, Usmani A, Szymanski JJ, Qaium F, Mudd J, Kim H, Tan B, Fields RC and Chaudhuri, AAi. ctDNA MRD detection from plasma and urine and personalized oncogenomic analysis in oligometastatic colorectal cancer. Abstract 543: ctDNA MRD detection from plasma and urine and personalized oncogenomic analysis in oligometastatic colorectal cancer. *Cancer Res* 1 July 2021; 81 (13_Supplement): 543. doi.org/10.1158/1538-7445.AM2021-543
11. **Pellini B**, Pejovic N, Harris PK, Feng W, Usmani A, Qaium F, Fields RC, Aadel A. Chaudhuri. Size-based enrichment of urinary cell-free DNA compared to plasma cell-free DNA for liquid biopsy analysis of oligometastatic colorectal cancer. *Int J Radiat Oncol Bio Phys* 2020 108:3_suppl, e552
12. **Pellini B**, Pejovic N, Feng W, Harris PK, Usmani A, Qaium F, Fields RC, Chaudhuri A. Urinary cell-free DNA analysis for tumor mutation detection in patients with oligometastatic colorectal cancer. *Journal of Clinical Oncology*. 2020 38:15_suppl, e15545-e15545
13. Afridi F, **Pellini Ferreira B**, Geigel E. A Rare Case of Papillary Endobronchial Squamous Cell Carcinoma. *American Journal of Respiratory and Critical Care Medicine* 2017; 195: A6569
14. **Pellini Ferreira B**, Baker KK, Redman M, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP. Predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP). *Journal of Clinical Oncology* Vol 33, No 15_suppl.e17065
15. Trasel AR, Anjos GM, **Ferreira BP**, Pirolli R, Freitas VL, Meurer L, Costa TD, Schwartzmann G. (2012, August 31). RC3095: pharmacokinetics of a bombesin receptor antagonist/gastrin-releasing factor. *Revista HCPA*; 32 (Suppl):121.
16. Trasel AR, Anjos GM, **Ferreira BP**, Pirolli R, Freitas VL, Meurer L, Costa TD, Schwartzmann G. (2012, August 31). RC3095: A new approach to treat solid tumors. *Revista HCPA*; 32 (Suppl):186-187.
17. Borba CM, Cadore E, **Ferreira BP**, Ziquinatti F, Pintos AK, Schulz R, Hillmann EC, Cohen CR, Graudenz MS. (2012, August 31). The expression of claudins 1,3,4,7 and E-Chaderin in a series of triple-negative breast cancer. *Revista HCPA*; 32 (Suppl):153.

18. Trasel AR, Anjos GM, **Ferreira BP**, Pirolli R, Freitas VL, Meurer L, Costa TD, Schwartzmann G. (2012, August 31). RC3095: pharmacokinetics of a bombesin receptor antagonist/gastrin-releasing factor. *Revista HCPA*; 32 (Suppl):121.
19. Trasel AR, Anjos GM, **Ferreira BP**, Pirolli R, Freitas VL, Meurer L, Costa TD, Schwartzmann G. (2012, August 31). RC3095: A new approach to treat solid tumors. *Revista HCPA*; 32 (Suppl):186-187.
20. Borba CM, Cadore E, **Ferreira BP**, Ziquinatti F, Pintos AK, Schulz R, Hillmann EC, Cohen CR, Graudenz MS. (2012, August 31). The expression of claudins 1,3,4,7 and E-Chaderin in a series of triple-negative breast cancer. *Revista HCPA*; 32 (Suppl):153.
21. Borba CM, Cadore E, Schulz R, Pintos AK, **Ferreira BP**, Graudenz MS, Hillmann EC, Cohen CR, Ziquinatti F. (2012, August 31). The prognostic correlation between claudins' expression and triple-negative breast cancer. *Revista HCPA*; 32 (Suppl):154
22. **Ferreira BP**, Anjos GM, Freitas VL, Barreiro G, Meurer L, Schwartzmann G. (2011, July 8). Phase I study of RC-3095, a new bombesin receptor antagonist/ gastrin-releasing factor administered intravenously in patients with advanced or refractory solid tumors that express the *GRP* gene. *Revista HCPA*; 31 (Suppl 1):76-77.

Oral Presentations

1. Yang JCH, Doucet L, Wang M, Fan Y, Sun M, Greillier L, Planchard D, Mazieres J, Felip E, **Pellini B**, Bosch-Barrera J, Cobo M, Bearz A, Paz-Arez LG, Bazhenova L, Shum E, Tiseo M, Soto Parra H, Zheng L, Janne PA. A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study. Abstract 8513. RAPID Oral Abstract Session. 2024 ASCO Annual Meeting. Chicago, IL. May 31- June 4, 2024.
2. **Pellini B***, Madison RW*, Childress M, Miller ST, Cheng J, Huang RSP, Krainock M, Gupta P, Zou W, Shames DS, Moshkevich S, Ballinger M, Liu MC, Young A, Srivastava MK, Oxnard GR, Socinski MA. Circulating tumor DNA monitoring informs maintenance outcomes in patients with advanced NSCLC treated with induction atezolizumab + carboplatin + nab-paclitaxel. 2nd Annual Hawaii Global Summit on Lung Cancer. Kona, Hawaii. June 27- July 1, 2023.
3. Arce K, Vazquez T, Simmons V, Gray JE, **Pellini B**. Minority patient-centered education initiative to increase knowledge about clinical trials in oncology. 2022 Moffitt Cancer Health Disparities Retreat. Tampa, Florida. December 2, 2022.
4. **Pellini B***, Pejovic N*, Feng W*, Earland N, Harris PK, Usmani A, Szymanski JJ, Qaium F, Mudd J, Petty M, Maher CA, Henke LE, Park H, Ciorba MC, Kim H, Mutch MG, Pedersen KS, Tan BR, Hawkins WG, Fields RC, Chaudhuri AA. ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine. National Institute of Health (NIH) Circulating Nucleic Acids/Liquid Biopsy Interest Group. ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine. November 10, 2020 (Virtual).

5. **Pellini Ferreira B**, Afridi F, Carilli A. *A sweet Hemoglobin*. Presented at ACP Florida Chapter 2016 Annual Residents & Medical Students Meeting. Orlando, FL. April 9, 2016.
6. **Pellini Ferreira B**, Carilli A. *Challenges in diagnosing rare silent tumors: a case report of hepatoid carcinoma of the pancreas*. Presented at ACP Florida Chapter 2015 Annual Residents & Medical Students Meeting. Orlando, FL. March 28, 2015.

Poster Presentations

1. **Pellini B**, Brown D, Decker B, Hughes J, Polisecki E, Sun D, Kuang Z, Xu C, Gasco A, Tukachinsky H.. Computational variant origin prediction (VOP) to distinguish germline, tumor somatic, and clonal hematopoiesis (CH) variants in liquid biopsy (LBx) Liquid Biopsy Annual Conference ISLB. Denver, CO. November 23- November 25, 2024.
2. **Pellini B**, Li J, Schell M, Tanvetyanon T, Creelan B, Chiappori A, Saltos A, Antonia S, Haura E, Shafique M, Rose T, Khalil F, Vafadar S, Smikker S, Melendez M, Aminpour A, Sansil A, Wermuth J, Sanchez AA, Ugrenovic M, Monteiro A, Rix U, Gray JE. A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer (SqCLC). Abstract 8545. 2024 ASCO Annual Meeting. Chicago, IL. May 31- June 4, 2024.
3. Avasthi K, Manley BJ, **Pellini B**, Bloomer AM, Fang B, Koomen JM, Siegel EM, Wang L. Distinct Proteome Profiles in Plasma Exosomes of Lung and Prostate Cancer Patients. 2024 Moffitt Scientific Symposium, Moffitt Cancer Center, May 7-8, 2024. Tampa, FL
4. Arce K, Vázquez T, Singh A, Ryan J, Sutton S, Gray J, Simmons V, Christy S, **Pellini B**. Methodology of a Study to Develop a Minority Patient-Centered Education Intervention to Increase Knowledge About Clinical Trials in Thoracic Oncology. 2023 Cancer Health Disparities Annual Retreat, Moffitt Cancer Center. December 1, 2023. Tampa, FL
5. Ozakinci H, Nazario G, Stern YE, Solanki HS, Chen D-T, Rose T, Schabath MB, Stewart P, Teer J, Beg A, Boyle TA, Haura EB, **Pellini B**. Rapid autopsy provides unique research opportunity to evaluate KRAS^{G12C} inhibitor resistance mechanisms in non-small cell lung cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA. October 11-15,2023
6. Janne PA, Bigot F, Papadopoulos K, Eberst L, Sommerhalder D, Lebellec L, Voon PJ, **Pellini B**, Kalinka E, Arbour K, Herzberg B, Boni V, Bodernave S, Lee HW, Ou SI, Riess JW, Beck JT, Ponz-Sarvise M, Ascierto PA, Choi YJ, Tan D, Yang M, Bao L, Raman R, Yang L, Mu Y, Wong S, Dua R, Johnson M. Preliminary Safety and Anti-Tumor Activity of RMC-6291, a First-in-Class, Tri-Complex KRASG12C(ON) Inhibitor in Patients With or Without Prior KRASG12C(OFF) Inhibitor Treatment. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA. October 11-15,2023
7. **Pellini B**, Madison RW, Childress M, Miller ST, Cheng JH, Huang RSP, Krainock M, Gupta P, Zou W, Shames DS, Moshkevich S, Ballinger M, Liu MC, Young A, Srivastava MK, Oxnard GR, Socinski MA. Circulating Tumor DNA (ctDNA) Monitoring Informs Maintenance Outcomes in Patients (pts) with Advanced NSCLC Treated with Induction Atezolizumab + Carboplatin + Nab-Paclitaxel (A + CnP). Abstract 9075. 2023 ASCO Annual Meeting. June 4, 2023.

8. Ozakinci H, Alongtaga A, Nazario G, Furlan CK, Koomen J, Perez B, **Pellini B**, Beg A, Haura E, Boyle T. Molecular Subtyping of Donated Small Cell Lung Carcinoma Samples With A Clinical Targeted Expression Panel (RNA Step). Moffitt Research Symposium. May 16, 2023.
9. Arce K, Aurelio J, **Pellini B**. HER2 exon 20 insertions in NSCLC: a case series of first-line pembrolizumab with or without chemotherapy followed by second-line trastuzumab-deruxtecan. 18th PHSU-PRI Annual Scientific Conference. Ponce, PR. May 6, 2023.
10. Stewart P, Solanki H, Welsh E, Stern Y, Imbody D, Zhang Y, **Pellini B**, Fang B, Yoder S, Eschrich S, Teer J, Koomen J, Haura EB. Proteogenomic landscape of KRASG12C lung adenocarcinomas reveals new subtypes and potential combination therapies. AACR Special Conference on Targeting RAS. 2023. March 5-8, 2023. Philadelphia, PA.
11. Gilardone S, **Pellini B**, Laborde J, Chen D, Melzer D Osimertinib versus Afatinib as First-EGFR Exon 19 Deletion or Exon 21 L858R Mutation. HOPA 2022. March 30 – April 2, 2022. Boston, MA
12. Soupier AC, Stewart P, Manley BJ, **Pellini B**, Zhang J, Mo Q, Marchion DC, Koomen J, Siegel E, Wang L. Effects of plasma exosome isolation methods on detectable multiomic profiles in cancer patients and healthy controls. AACR 2022. April 8-13, 2022. New Orleans, LA.
13. **Pellini B**, Pejovic N*, Feng W*, Earland N, Harris PK, Usmani A, Szymanski JJ, Qaium F, Mudd J, Kim H, Tan BR, Fields RC, Chaudhuri A. ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine. AACR 2021. April 9-14, 2021.
14. **Pellini B**, Ganesan V, Wan F, Sankararaman S, Manyanont S, Akhave N, Baggstrom M, Ward J, Waqar S, Morgensztern D, Govindan R, Devarakonda S. Clinical characteristics and outcomes in patients with *KRAS* G12C mutated non-small cell lung cancer. Poster presented at IASLC WCLC 2020. January 28-21, 2021.
15. **Pellini B**, Hasan S*, Samson P, Earland N, Ward N, Waqar SN, Baggstrom M, Robinson C, Govindan R, Devarakonda S, Morgensztern D. Chemoradiation with cisplatin-etoposide versus carboplatin-etoposide in limited-stage small-cell lung cancer. Poster presented at IASLC WCLC 2020. January 28-21, 2021.
16. Antao N, Samson P, **Pellini B**, Waqar SN, Devarakonda S, Ward J, Govindan R, Morgensztern D. Cause of death in patients with squamous cell lung cancer treated with surgery. Poster presented at IASLC WCLC 2020. January 28-21, 2021.
17. **Pellini B**, Pejovic N, Harris PK, Feng W, Usmani A, Qaium F, Fields RC, Chaudhuri AA. Size-based enrichment of urinary cell-free DNA compared to plasma cell-free DNA for liquid biopsy analysis of oligometastatic colorectal cancer. Poster presented at ASTRO, 2020. October 25, 2020.
18. **Pellini B**, Nadja Pejovic N*, Feng W, Harris PK, Usmani A, Szymanski JJ, Mudd J, Henke LE, Kim H, Tan BR, Hawkins WG, Fields RC, Chaudhuri AA. ctDNA MRD

detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine. Poster presented at RRS,2020. October 18, 2020.

19. **Pellini Ferreira B**, Morgensztern D. A Phase II, Open-Label Study of RRx-001 and Nivolumab in Patients with Small Cell Lung Cancer Previously Treated with a Platinum-Based Regimen (EPI 1). Poster presented at Washington University Fellow's Fall Symposium, November 13, 2018.
20. Ayad N, **Pellini Ferreira B**, Ali S. Multiple Myeloma Presenting as Bilateral Central Retinal Vein Occlusion. Poster presented at FMA Annual Meeting 2017, August 4, 2017.
21. Almkhtar T, **Pellini Ferreira B**, Carilli A. An Unusual Case of Bleeding Diathesis: A Resilient Acquired Factor VIII Inhibitor. Poster presented at ACP Florida Chapter 2016 Annual Residents & Medical Students Meeting, April 9, 2016.
22. Kinan M, **Pellini Ferreira B**, Otoy J. Systemic Therapy in Primary Squamous Cell Carcinoma of the Duodenum: A Case Report. Poster presented at: Florida Medical Association David A. Paulus, M.D., Annual Poster Symposium; Orlando, FL. August 1, 2015;
23. Afridi F, **Pellini Ferreira B**, Diaz DD, Lanser M J. The Importance of Physical Examination: Delay in the Diagnosis of a Squamous Cell Carcinoma of the Uvula. Poster display at ACP Florida Chapter 2015 Annual Residents & Medical Students Meeting, March 28, 2015.
24. **Ferreira BP**, Anjos GM, Freitas VL, Barreiro G, Meurer L, Schwartzmann G. (2011). Phase I study with RC-3095, a new bombesin receptor antagonist/ gastrin-releasing factor administered intravenously in patients with advanced or refractory solid tumors that express the *GRP gene*. Poster presented at 31st Scientific Meeting of Hospital de Clinicas de Porto Alegre; Porto Alegre, Brazil.

Digital Scholarship

Media interviews:

1. 2025 Women in Oncology at Moffitt.
<https://www.moffitt.org/globalassets/pdfs/publications/women-in-oncology/moffitt-women-in-oncology.pdf>
2. Genomeweb. Precision Medicine Online. Foundation Medicine Monitoring Assays Show Promise for Guiding Lung Cancer Chemo-Immunotherapy. Published October 2, 2023. <https://www.precisionmedicineonline.com/molecular-diagnostics/foundation-medicine-monitoring-assays-show-promise-guiding-lung-cancer-chemo>
3. eCancer. Best of ASCO Miami 2023. Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA. Published July 7, 2023. <https://ecancer.org/en/video/11398-liquid-biopsies-and-cancer-the-role-of-ngs-ctc-exosomes-cfdna-and-cfrna>

4. CURETODAY. ASCO 2023. CtDNA May Help Predict Lung Cancer Outcomes, Guide Treatment. Published June 7, 2023. <https://www.curetoday.com/view/ctdna-may-help-predict-lung-cancer-outcomes-guide-treatment>
5. FOX 13 Tampa Bay. Early detection of lung cancer can help save lives, health experts say. August 1, 2022. <https://www.fox13news.com/news/early-detection-of-lung-cancer-can-help-save-lives-health-experts-say>
6. VJONCOLOGY. ASCO 2022. ctDNA MRD detection in patients with NSCLC. June 5, 2022. <https://www.vj oncology.com/video/iklxmk170py-ctdna-mrd-detection-in-patients-with-nsclc/>
7. VJONCOLOGY. ASCO 2022. Applications of ctDNA in oncology. June 5, 2022. https://www.vj oncology.com/video/1v_tpeoqb-8-applications-of-ctdna-in-oncology/
8. VJONCOLOGY. ASCO 2022.ctDNA sensitivity in early-stage disease. June 5, 2022. <https://www.youtube.com/watch?v=vYxQtiFnFLY>
9. The ASCO Post. Expert point of View: Bruna Pellini, MD. October 25, 2021. <https://ascopost.com/issues/october-25-2021/epov-bruna-pellini/>
10. Bay News 9. State of Lung Cancer Report. Bay News 9. November 16, 2021. https://archive.tveyes.com/18120/3323884-182740/763831ab-a4bc-4bec-805d-84f957df08ab/BN9_11-16-2021_20.34.25.mp4
11. VJONCOLOGY. The Video Journal of Oncology. ASCO 2021-Checkpoint inhibitors alone or with chemotherapy in lung cancer. May 25, 2021. <https://www.vj oncology.com/video/vwjdrc-8ie-checkpoint-inhibitors-alone-or-with-chemotherapy-in-lung-cancer/>
12. VJONCOLOGY. The Video Journal of Oncology. AACR 2021-Future Approaches to Treating colorectal cancer. April 7, 2021. <https://www.vj oncology.com/video/ni1u9mrc3rg-future-approaches-to-treating-colorectal-cancer/>
13. CLINICAL LM. Lab Manager. Liquid Biopsies Offer Quicker, Easier Lung Cancer Testing. Jan 8, 2021. <https://www.clinicallabmanager.com/news/liquid-biopsies-offer-quicker-easier-lung-cancer-testing-24809>
14. Cancer Network. Home of the journal ONCOLOGY. Bruna Pellini, MD, on the Approval of the Guardant360 CDx. September 18, 2020. <https://www.cancernetwork.com/view/bruna-pellini-md-on-the-approval-of-the-guardant360-cdx>